Amur Minerals Corporation

Amur Minerals Corporation

AMMCF
Amur Minerals CorporationUS flagOther OTC
0.04
USD
- -
- -
1.38MMarket Cap
2012 Y
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
Revenue per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Basic EPS, GAAP
-1.15
-0.96
-0.32
-0.17
-1.37
-0.22
-0.64
-0.38
-0.29
-0.1
-0.29
-0.87
- -
Free Cash Flow per Basic Share
-0.75
-0.66
-0.73
-1.81
-1.91
-2.26
-0.88
-0.08
-0.06
-0.04
- -
- -
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
2.84
- -
Book Value per Share
5.96
6.3
5.67
6.98
7.03
6.05
6.18
5.59
4.82
3.69
3.83
-0.01
- -
Tangible Book Value per Share
-0.4
-0.08
0.57
1.34
6.09
-0.36
4.54
4.39
3.44
2.59
2.64
0.37
- -
Basic Weighted Avg Shares
2
2
3
3
3
4
4
5
7
9
9
9
- -
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
-3,520
Depreciation Expense
- -
- -
- -
- -
1
- -
- -
- -
- -
- -
- -
- -
- -
Net Income, GAAP
-2
-2
-1
- -
-5
-1
-3
-2
-2
-1
-2
-8
-1
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
-2,428
Working Capital
5
7
6
7
5
2
-1
- -
2
4
2
3
1
LT Debt
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Total Equity
16
18
13
15
21
21
19
21
23
22
23
3
1
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
-21.62
-16.54
-5.73
-2.78
-21.69
-3.61
-10.74
-6.87
-6.68
-2.79
-7.65
- -
- -

Capital Structure

FRC

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-7.72%
-25.84%
-54.44%
Free Cash Flow
- -
- -
204.46%
Net Income, GAAP
117.44%
49.33%
-91.98%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
-99.81%

Quarterly Revenue

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
- -
- -
- -
- -
-0.29
2023
- -
- -
- -
- -
-0.87
2024
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
2.84
2024
- -
- -
- -
- -
- -

Company Description

APIChatGPT
CEO
Robin Jay Young
Full Time Employees
4
Sector
Basic Materials
Industry
Industrial Materials
Address
Kingston Chambers Road Town Virgin Islands, British
IPO Date
Sep 25, 2012
Business
Amur Minerals Corporation (ticker: AMMCF) operates as a cash shell following the divestiture of its mineral exploration assets; it pursues reverse takeover opportunities in the healthcare sector, notably through the acquisition of Extruded Pharmaceuticals Ltd, a UK-based drug delivery technology company focused on enhancing cancer treatments for solid tumors via local chemotherapy delivery. The company's principal former asset was the Kun-Manie nickel-copper sulphide project in Russia's Far East, encompassing nickel, copper, cobalt, platinum group metals including platinum and palladium, gold, and silver deposits across five wholly-owned deposits spanning 36 square kilometers in Amur Oblast; engineering studies confirmed economically viable open-pit and underground mining with flotation processing capabilities positioning it as a potential major global sulphide nickel producer. Founded in 2004 and headquartered in Road Town, British Virgin Islands, Amur Minerals previously concentrated on mineral property evaluation and development exclusively in the Far East of Russia. In March 2023, the company completed the sale of Kun-Manie to Bering Metals LLC for US$35 million, received in full by May 2024, transitioning it to cash shell status and relieving it of ongoing Russian project obligations including the mine plan development. In May 2024, shareholders approved a reverse takeover of Extruded Pharmaceuticals for GBP5.5 million in shares, alongside a name change to CRISM Therapeutics Corp, a 1-for-160 share consolidation, board changes, and re-admission to AIM; the target company's lead product, ChemoSeed, involves implanting chemotherapy directly into tumors such as high-grade gliomas, with plans for a Clinical Trial Application in H2 2024 and Phase II trials in Q4 2025. Further, discussions with Ascent Resources plc for a potential takeover ended in August 2023, and the company reported a pretax profit of USD512,000 in 2023 versus a prior-year loss.